Catalyst Wire Dossier Catalyst Wire Dossier

Vesemnogene Lantuparvovec

· Lantu Biopharma
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Vesemnogene Lantuparvovec, covering 2025-07-22 to 2025-12-04. Get the full timeline:

Most recent: Clinical Trial Update: Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC). [Phase 3]

See pricing